Neola Medical

Neola Medical EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Neola Medical (NEOLA.ST) as of Oct 21, 2026 is -1.90. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.90 — a change of -0.33% (higher).

EV/FCF

-1.90

YoY

-0.33%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Neola Medical is 2025 -1.90 . EV/FCF (Enterprise Value to Free Cash Flow) of Neola Medical was 2024 -1.90 . It decreases by -0.33% higher compared to the previous year.

The Neola Medical EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-19.28 SEK
Jan 1, 2019
-12.45 SEK
Jan 1, 2020
-5.43 SEK
Jan 1, 2021
-2.21 SEK
Jan 1, 2022
-1.06 SEK
Jan 1, 2023
-2.11 SEK
Jan 1, 2024
-1.90 SEK
Jan 1, 2025
-1.90 SEK
The Neola Medical EV/FCF history
YEAREV/FCFYoY
-1.90-0.33%
-1.90-10.07%
-2.11+98.72%
-1.06-51.77%
-2.21-59.36%
-5.43-56.40%
-12.45-35.44%
-19.28-59.97%
-48.17+316.78%
-11.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neola Medical Stock analysis

What does Neola Medical do? Neola Medical AB commercializes medical devices based on its patented GASMAS technology for continuous lung monitoring in premature babies. The company's primary product, NEOLA, provides real-time alerts for life-threatening complications by measuring lung volume changes and oxygen concentration. Neola Medical targets neonatal intensive care units as its key market segment, serving healthcare providers who require advanced monitoring solutions for premature infants. The firm's revenue model relies on selling the NEOLA device and associated technology to hospitals and medical facilities specializing in neonatal care. The company's business concept centers on the commercialization of its medical technology product for continuous lung monitoring, leveraging the GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical focuses on the neonatal intensive care market segment, where its device offers continuous monitoring capabilities that address critical needs in premature infant care. The primary purpose of the NEOLA device is to support neonatal intensive care through real-time monitoring and alerts for complications. Neola Medical AB's revenue streams come from the sale of the NEOLA medical device and its underlying technology to healthcare institutions. The company targets neonatal intensive care units as its primary customer segment, focusing on hospitals and medical facilities that provide specialized care for premature babies. The firm's business model is built around the commercialization of its patented GASMAS technology through the NEOLA device, which addresses specific monitoring needs in neonatal care. Neola Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neola Medical stock

EV/FCF (Enterprise Value to Free Cash Flow) of Neola Medical is -1.90 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Neola Medical changed from -1.90 to -1.90, representing a -0.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Neola Medical since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Neola Medical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neola Medical

All Key Metrics — Neola Medical